Tag: Research

TD Asset Management, Inc: Private Company Information #td #asset #management, #inc. #company #information, #key


Company Overview of TD Asset Management, Inc.

Company Overview

It provides its services to individuals and high net worth individuals. The firm also caters to governments, group RRSP’s, pension funds, corporations, charitable organizations, small and medium sized businesses, institutions, endowments, and foundations. It manages separate client-focused portfolios. The firm also launches and manages equity, fixed income, and balanced mutual funds for its clients. It also launches and manages hedge funds for its clients. The firm invests in the public equity and fixed income markets across the globe. It was founded in 1987 and is based in Toronto, Ontario with additional offices across North America. TD Asset Management Inc. operates as a subsidiary of The.

It provides its services to individuals and high net worth individuals. The firm also caters to governments, group RRSP’s, pension funds, corporations, charitable organizations, small and medium sized businesses, institutions, endowments, and foundations. It manages separate client-focused portfolios. The firm also launches and manages equity, fixed income, and balanced mutual funds for its clients. It also launches and manages hedge funds for its clients. The firm invests in the public equity and fixed income markets across the globe. It was founded in 1987 and is based in Toronto, Ontario with additional offices across North America. TD Asset Management Inc. operates as a subsidiary of The Toronto-Dominion Bank.

Canada Trust Tower

Toronto, ON M5J 2T2

Key Executives for TD Asset Management, Inc.

Chief Executive Officer and Chief Investment Officer

President and Director

Chief Financial Officer, Chief Operating Officer, Chief Risk Officer and Director

Managing Director and Head of Relationship Management

Managing Director and Portfolio Manager

Compensation as of Fiscal Year 2016.

TD Asset Management, Inc. Key Developments

TD Asset Management Inc. Announces Intention to Terminate Operations of the TD Asian Growth Class

TD Asset Management Inc. (TDAM) announced its plans to terminate operations of the TD Asian Growth Class due to a low number of unit holders. Effective May 25, 2017, the terminating fund is closed to additional purchases, including pre-authorized contribution plans, and will be terminated on or about August 10, 2017. Unit holders may redeem or switch their holdings in the terminating fund for settlement on, or prior to, the termination date. As at August 10, 2017, TDAM will liquidate the holdings of the terminating fund at fair market value, determine distributions and distribute the net assets to unit holders.

TD Asset Management Inc. Launches TD Managed ETF Portfolios

TD Asset Management Inc. announced the launch of TD Managed ETF (Exchange Traded Funds) Portfolios (the Portfolios). These low-cost managed portfolios of TD index-tracking exchange traded funds (TD ETFs) are designed to meet a range of investor risk profiles and are currently available for self-directed investors as D-Series mutual funds.

TD Asset Management Inc. Introduces the Epoch Global Shareholder Yield Currency Neutral Fund and the TD U.S. Low Volatility Currency Neutral Fund

TD Asset Management Inc. announced the launch of two currency neutral funds: the Epoch Global Shareholder Yield Currency Neutral Fund and the TD U.S. Low Volatility Currency Neutral Fund. For investors seeking foreign equity exposure, the funds seek to minimize the impact that currency fluctuations can have on the funds’ underlying investments. Whether investors are seeking a currency neutral solution with a low volatility U.S. equity focus, or a broader global equity option that can deliver regular income, the funds strive to deliver consistent and strong risk-adjusted returns over the longer term.

Similar Private Companies By Industry

Tags : , , , , , , , , ,

Research center for arts and culture #research #center #for #arts #and #culture



Environmental science major Avery Palardy ’15 and Earth and Environmental Sciences department assistant professor Vasilii Petrenko examine a carbon 14 extraction line used to study methane found in ancient ice samples.

The University of Rochester has been a pioneer in fields as diverse as geology, optics, medicine, economics, political theory, and human behavior.

A compact campus works to our advantage. All units of the University are within a 10-minute walk or drive, facilitating a highly collaborative, multidisciplinary research environment.

Research at the University of Rochester Medical Center famous for its role in developing three vaccines now used worldwide is a $232 million enterprise involving thousands of scientists, and more than 1,100 individual clinical research projects.

A Blue Gene Q supercomputer. capable of more than 200 trillion calculations a second. An Omega 60-beam laser that can deliver up to 40,000,000,000,000 watts of power onto a target less than 1 millimeter in diameter for approximately one-billionth of a second.

Tools like these are crucial assets for faculty and student research.

Rochester’s historic tradition as a center of manufacturing excellence, especially in optics and photonics, has helped it transition to a knowledge-based economy. And as the city’s leading employer. the University has been a key catalyst.

212 inventors from 51 University departments and units filed invention disclosures in fiscal year 2012. When measured against its peers, the University of Rochester is one of the most productive institutions in the nation in terms of royalty generation.

For more than 150 years. the University has been a pioneer in fields as diverse as geology, optics, medical education, economics, political theory, and human behavior.

Research Strategic Plan 2013-2018

“The committee identified four broad areas of research synergy across the University: Data Science, Research Foundations for a Healthier Society, Light and Sound, and Energy and the Environment. In addition, we identified an emerging emphasis on community engagement and the translation of research discoveries into practical benefits for society.”
Read / download the complete plan

Big Data at the University of Rochester

Data science is a defining discipline of the 21st century, and the top priority in the 2013-2018 research strategic plan.

Research at a Glance

Student-to-faculty ratio provides a highly collegial research environment.

Top 50
In federally financed research and development expenditures to academic institutions. (National Institutes of Health, 2015)

Top 20
Among U.S. institutions for relative citation impact.

$361 million
Research funding received in FY2016.

Percentage of undergraduate students within Arts, Sciences & Engineering who engage in research.

FY 2016 Research Profile

Proposals submitted: 1,929

Sponsored research expenditures: $351 million

Invention disclosures: 142, from 201 inventors in 48 departments with 44 collaborators from 27 outside institutions

Copyright registrations filed: 3

Patents: 48 U.S. and 21 foreign granted, covering 56 different technologies

Licensing agreements: 31 new agreements

Licensing revenue: $22.0 million


Research Sites by School or Division

UR Ventures: We’ll help make your idea a reality. Technology commercialization at the University of Rochester.

Futurity.org: Discover the future with news from leading research universities

River Campus (mailing address): 500 Joseph C. Wilson Blvd. Rochester, NY 14627

River Campus (GPS/maps): 252 Elmwood Ave. Rochester, NY

Medical Center: 601 Elmwood Ave. Rochester, NY 14642

Eastman School: 26 Gibbs St. Rochester, NY 14604

Tags : , , , , ,

School of Psychology: University of Sussex #undergraduate, #psychology, #study, #postgraduate, #masters, #phd, #research


School of Psychology

We offer both undergraduate and postgraduate courses. By choosing Psychology at Sussex you will study in one of the largest psychology departments in the UK. Our research is ranked among the top 10 in the country [REF2014]. You will work alongside renowned researchers and on your own projects to help develop key skills to boost your employment prospects. Throughout your study, our staff will be on hand to offer support and guidance.

Why Psychology at Sussex?

People and Contacts

By choosing Sussex you will be studying at a university ranked in the Top 10 in the UK for Psychology research

The School of Psychology currently holds an Athena Swan Bronze Award

Excellence in Research

  • Our research was ranked seventh in the UK for research impact and 10th overall in the country, in the Research Excellence Framework [REF2014].
  • At Sussex you will be given the chance to work alongside world-renowned researchers.
  • Psychology at Sussex was ranked 10th out of 82 submissions in the Research Excellence Framework 2014 (REF2014).

Excellence in Teaching

  • We have one of the largest psychology departments in the UK and as a result of this, have specialists in every discipline.
  • We have more than 50 teaching faculty, all of whom are actively engaged in research, so whatever your passion for psychology we have the expertise to support you.
  • We offer British Psychological Society (BPS) accredited undergraduate degrees.
  • We offer a range of masters and doctorate degrees.

Excellent league table rankings

We are ranked in the top 20 across all major league tables:

  • 11th in the Complete University Guide 2018.
  • 14th in the Times and Sunday Times Good University Guide 2017.
  • 18th in the Guardian University Guide 2018.

Excellent career prospects

  • We are ranked 1st in the UK for graduate prospects (Guardian University Guide 2018).
  • You will get involved in research and be given the opportunity to take part in some of our research schemes, which will equip you with a range of skills for the work place. These skills include numeracy, critical thinking, problem solving, communication, working to deadlines and independent working.
  • By studying at Sussex you will be given the opportunity to forge links with top employers on our student placements.

School of Psychology internal website

Information for current staff and students

Tags : , , , , , ,

King – s Clinical Trials Unit #clinical #trials #unit, #clinical #trials #units, #clinical #trial


King s Clinical Trials Unit

The King s Clinical Trials Unit is fully registered by the UKCRC and receives support funding from NIHR NETSCC and the biomedical research centre for mental health. The UKCRC registered King s Clinical Trials Unit is available to provide support to academic led trials across KHP and externally.

For academic collaborations with statistics, health economics, trial management or data management, the KCTU must be approached at the grant application stage, ideally 3-4 months in advance of the submission deadline. Requests for academic collaboration made post-funding award or close to the submission deadline are unlikely to be successful.

Currently there are approximately 175 ongoing academic led clinical trials sponsored or co-sponsored by a KHP organisation.

The King s CTU is part of the Department of Biostatistics and has been awarded full CTU registration by UKCRC.


Service level support for web based randomisation and eCRF systems are usually available to all trials. Requests for service level support may be submitted at any time, whether pre- or post-funding award. The costing model for these services can be found under the KCTU Support or by visiting the links below. These are provided publicly to help researchers estimate likely costs, but it is recommended that a formal quote is requested prior to grant submission.

As KCTU receives infrastructure support from NIHR, priority for academic collaborations will be given to NIHR funding streams. KCTU support or collaboration is agreed formally at monthly senior management meetings.

To request support, please submit a completed support request form here .

The KCTU manages a bespoke online randomisation system, supporting simple randomisation, block randomisation, stratified block randomisation and minimisation.

The KCTU has hosted a commercial data entry system (InferMed MACRO) since 2005. It has also been used for other complex intervention trials.

Statistical input into research is vital to ensure that data is robustly collected and analysed, thereby providing reliable results which are publishable in high impact journals.

A team of health economists with expertise in conducting high quality economic evaluations of healthcare interventions, modelling studies and cost analyses.

Effective trial management pulls all critical elements of a trial together to ensure its successful delivery on time, within budget and to a high standard.

No study is better than the quality of its data capturing good quality data that is valid, auditable, contemporaneous, accurate is essential.


Find us on social media!


The King’s CTU is part of the Department of Biostatistics and has been awarded full CTU registration by the UK Clinical Research Collaboration (UKCRC). This unit receives National Institute for Health Research CTU Support Funding. This funding has been awarded to support the unit in developing and supporting NIHR trials.

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. You can change your cookie settings at any time. Otherwise, we will assume you have agreed to continue. For more information on cookies and how to disable them visit

Domain name provided by


Clinical Trials Unit
King’s College London
PO64, Room M2.06
Institute of Psychiatry
16 De Crespigny Park, London

Tags : , , , , , , , , , , , , , , , , ,

International Journal of Business Science and Applied Management (IJBSAM) #academic #journal, #business #science, #applied


International Journal of
Business Science and Applied Management

Aiming to be the de facto business and management open access journal!

Authors are invited to submit theoretical and empirical papers in all categories of business such as e-business, general management, international business, strategy, marketing, supply chain management, organization studies, entrepreneurship, enterprise, innovation and human resource management. This list is not meant to be exhaustive, but rather an indication of the areas of concern of the journal.

We welcome paper submissions on the basis that the material has not been published elsewhere. We also aim to develop a journal that will appeal to both business and management practitioners. On that basis, papers that include practical applications to any business and management field are welcomed.

We endeavour to provide rapid and informative feedback to authors. Our objective is to obtain reviews from referees within 10 weeks of the initial paper submission. For the author guidelines and for submitting an article please click here. We are looking forward to receiving quality submissions for our forthcoming volumes. In 2014 we received about 250 papers out of which we only accepted about 4%, after a rigorous double blind review process. All papers are available for free as we are an open access journal.

Recently Published Papers

Simulation and assessment of agricultural biomass supply chain systems

Agricultural biomass supply chain consists of a number of interacted sequential operations affected by various variables, such as weather conditions, machinery systems, and biomass features. These facts make the process of biomass supply chain as a complex system that requires computational tools, e.g. simulation and mathematical models, for their.

Sustainable wine supply chain and entrepreneurship. The exploitation of by-products in a waste management process

The sustainability issue has been acknowledged as a universal contemporary challenge within an entirely new, unprecedented and irreversible global economic, social, cultural and physical contemporary environment. Critical role plays the interdisciplinary Supply Chain Management (SCM) and its advance to sustainable SCM and more recently to green SCM. The field of.

Innovative Agrifood Supply Chain Network:Leading to traditional, “back to the future” foods

The agrifood sector is faced with major challenges that arise from changes in the sector’s economic and non- economic environments, to changes in consumers’ lifestyles, from global increases in food consumption, to diminishing production base and now days from the not stable political and economic situation and the continuous global.

Conceptual design of a telecommunications equipment container for humanitarian logistics

Preparedness addresses the strategy in disaster management that allows the implementation of successful operational response immediately after a disaster. With speed as the main driver, product design for humanitarian aid purposes is a key factor of success in situations of high uncertainty and urgency. Within this context, a telecommunications container (.

Do freight transport time savings translate to benefit for transport consuming companies?

It is common practice in Benefit – Cost analysis to consider freight transport time savings (FTTS) as a benefit for both transport producing and consuming companies. While transportation projects and policies resulting in FTTS are expected to have a positive effect on carriers’ performance reducing time related transport costs and.

Editorial: Supply Chain Management

This special issue has followed up the 3rd Olympus International Conference on Supply Chains held on Athens Metropolitan Expo, November 7 ?>

Tags : , , , , , , , , , , , , , ,

IBL international #supplier, #enzyme #assays, #radio #assays, #luminescence #assays, #immunoassays, #antibodies, #for #research, #for


IBL International immunoassays
for clinical diagnostics and research.
Empowered with Tecan .

Immunodiagnostics expert

IBL International part of the Tecan Group is an expert diagnostics provider focusing on special and rare indications. The company has over 30 years of experience in the development, manufacture and supply of immunoassays including enzyme, radiolabeled, and luminescence-based assays for research and routine diagnostics.

We are a pioneer and market leader in saliva diagnostics, offering a broad portfolio of luminescence- and ELISA-based tests for analytes such as cortisol, testosterone, estriol and various interleukins. The company also offers a number of specialist diagnostic assays for Endocrinology, neurotransmitters and Infectious disease in clinical diagnostics, along with key assays for the research segment, including HMGB1 and NF Light. By combining IBL International s immunodiagnostics expertise with Tecan s long tradition in serving the clinical diagnostic market, many of these assays have been specifically optimized for fully automated processing on the Freedom EVOlyzer or Freedom EVO platforms, offering complete solutions for the biochemical diagnosis.

IBL International products are available worldwide, through dedicated Tecan sales teams in the US, Europe and China, as well as an extensive distributor network and worldwide support from Tecan’s regional offices. An experienced team of product managers and customer service staff ensure the rapid support necessary in a clinical environment, and the company’s active research and development program has close ties with academic centers and commercial partners around the world.

All the company s assays have been designed with uniform pipetting procedures and shared reagents offering easy adaptation for automated Tecan liquid handling platforms and are manufactured to meet the highest global regulatory requirements and quality standards. IBL International is certified under ISO 9001, ISO 13485 and CMDCAS, meets GMP regulations and is audited by the US FDA. Combining these high quality assays with Tecan s flexible automated solutions offers exceptional productivity, throughput and reproducibility for clinical diagnostics and research.

Discover our immunoassays

Zika virus IGM – capture ELISA

The World Health Organization has declared the Zika virus an international public health emergency, prompted by growing concern that it could cause birth defects. As many as four million people could be infected by the end of 2016.

Highly sensitive and specific ELISA based on -capture technique for the determination of IgM antibodies as an aid in the serologic diagnosis of Zika virus infection.

Testosterone Saliva ELISA

The improved IBL International Testosterone Saliva ELISA is calibrated to the LC-MS/MS reference method and includes interchangeable reagents within the IBL saliva ELISA product line. Our assay can easily be automated on open platforms and shows good correlation to the manual runs.

Saliva Diagnostics

BI Intelligence – All-Access Membership – Business Insider Research Subscription Service #printing #business #cards

#business intelligence


A Gold Mine of Research and Knowledge at Your Fingertips

For the professional who wants daily downloads of the most important news and deep dives into the game-changing trends behind the news, the ALL-ACCESS service level is perfect for you.

With this level of membership, you have access to everything BI Intelligence produces: All of our insightful newsletters, all our latest research reports, complete access to our archive of past reports, plus a steady stream of extra data and research you won’t find anywhere else.

Here’s everything you get with your membership…

  • All 6 of our insightful newsletters
  • Every comprehensive research report we release
  • Access to the extensive research reports archive
  • A convenient online research center

Activate your membership today »


Our reports are packed with data, insights and analysis to help you understand your chosen subject area in fresh new ways.

As an ALL-ACCESS member, you get complete access to the scores of valuable reports we research and write each year, including popular titles like:

  • E-Commerce Benchmarks Report
  • The Mobile Point-of-Sale Report
  • The Connected Home Report
  • The Ad Viewability Report
  • The Mid-Year Smartphone Update Report
  • The Payments Ecosystem Report
  • The Subscription Revenue Report
  • The Remittances Explainer
  • The IoT Report
  • The Fintech Ecosystem Report

You’ll receive nearly a dozen reports each month, delivered electronically the instant they’re finalized. You’ll also have complete access to our archive of over 100 past reports any time you need them.


With access to all 6 of our newsletters, you’ll know about all the important developments in the digital industry that are impacting your company, your bottom line, and even your career.

Our newsletter services give you the context around critical developments so that you can run your business more efficiently, more profitably and more successfully.

Every morning the BI Intelligence team will deliver you a daily newsletter covering everything you need to know in your digital industry:

  • The insights you need to make smarter decisions
  • The new trends that can disrupt your existing business or open up exciting new opportunities
  • The strategies your competitors are pursuing (so you can stay one step ahead of them!)
  • The right moves to grow your business and advance your career

I have found at least one great piece of new, useful information in the BI Intelligence newsletters every single day. They are quick and to-the-point. BII is coming out with new and insightful information every single day.”

— Peter Sedlarcik
EVP – Business Insights & Intelligence
Havas Media

BI Intelligence is one of the main resources I use on a daily basis to stay ahead of the ever-changing digital media curve. The BII research team publishes great charts and reports in a timely manner. I find about 4 or 5 reports to be useful every month.”

— Francis Che
Head Of Insights Strategy & Research – Apa

Tags : , , , , , , , , ,

SIB: School Of Investment Banking #sib, #school #of #investment #banking, #equity #research, #credit #analysis,


Lorem Ipsum is simply dummy text

“Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged.Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged.

About Us

Founded in 2007, by a former banker from Lehman Brothers, The School of Investment Banking is a unique and one of a kind Investment Banking training institute. What sets us apart is the fact:

That we leverage our deep contacts with recruiters to secure world class placement opportunities for candidates

With an average placement record of 90% since inception, we know more than a thing or two about getting your foot in the door!

Top Science College in India #science #college #in #india, #nmims, #sunandan #divatia #school #of



Sunandan Divatia School of Science was started in 2007 with a view to provide undergraduate and post graduate students an opportunity to be a part of the unique learning methodology of the university, which lays emphasis on academic excellence combined with industry oriented training. With the boom in information technology and more and more sophistication in instrumentation techniques, there is now a very thin dividing line between the various disciplines of science. Therefore, there is a greater need for flexibility in scientific thought as well as training manpower on an interdisciplinary plane. With this thought in view, the SVKM’s NMIMS introduced, highly innovative and unique interdisciplinary courses at the School of Science from the academic year 2007-2008. The goal of the Sunandan Divatia School of Science is to be a Center of Excellence in the domain of Pure and Applied Science by providing quality education and research.

  • Ph.D. program in Biological Sciences and Chemistry (Regular & Professional)
  • Integrated M.Sc. – Ph.D. program in Biological Sciences and Chemistry
  • M.Sc. in Statistics, Biological Sciences and Chemistry (Analytical & Organic)
  • Masters of Physiotherapy
  • B.Sc. in Applied Statistics and Analytics
  • Integrated M.Sc. in Biomedical Science

All the Curriculums offered at the Sunandan Divatia School of Science are programs involving ‘Research’ and hence research constitutes a major thrust in all the programs. The focus is to generate a pool of highly qualified scientific talent who can fulfil the needs of Research Institutions as well as the demands in an industry setting. Thus the programs ensure employability; address global demands and community development.


Top News

Cell Culture Workshop – 2017

National Science Day – 2017

Continuing Physiotherapy Education in ICU

Sankhyiki 2017

Cover Page Features Our Research On Biosensors

Biomedical Research Journal – April 2017

Multiple Myeloma Symptoms, Treatments, and Survival Rates #multiple #myeloma, #multiple #myeloma #symptoms, #multiple #myeloma


Multiple Myeloma

Multiple myeloma is a blood cancer related to lymphoma and leukemia. Though it can’t usually be cured, there are treatments that slow down its spread.

What Is Multiple Myeloma?

In multiple myeloma, a type of white blood cell called a plasma cell multiplies unusually. Normally, they make antibodies that fight infections. But in multiple myeloma, they release too much protein (called immunoglobulin) into your bones and blood. It builds up throughout your body and causes organ damage.

The plasma cells also crowd normal blood cells in your bones. They release chemicals that dissolve bone. The weak areas of bone this creates are called lytic lesions.

As multiple myeloma gets worse, those plasma cells begin to spill out of your bone marrow and spread through your body. This causes more organ damage.


No one knows what causes multiple myeloma. But you’re more likely to get it if:

  • You’re older than 65
  • You’re African-American
  • You have a family member with it

If you have one these other plasma cell diseases, you may be more likely to get multiple myeloma:

  • Monoclonal gammopathy of undetermined significance (MGUS)
  • Solitary plasmacytoma


Early on, multiple myeloma may cause no symptoms. As time passes, you may have:

  • Bone pain
  • Weakness and fatigue
  • Weight loss

In rare cases, plasma cells may form purplish lumps that you can see underneath your skin. Your doctor may call them extramedullary plasmacytomas.



Your doctor may test you for multiple myeloma if a blood test shows you have:

  • Too much calcium in your blood (your doctor may call it hypercalcemia)
  • Anemia (too few red blood cells)
  • Kidney problems
  • High protein levels in your blood combined with a low albumin level (your doctor may say you have a “globulin gap”)

If your doctor thinks you have multiple myeloma, he’ll test your blood, urine, and bones. Some tests he may order include:

  • Electrophoresis, which measures immunoglobulin
  • Blood urea nitrogen, also known as BUN, and creatinine. These check how well your kidneys are working.
  • A CBC, which stands for complete blood count. It measures and counts the cells in your blood.

After your test results come in, your doctor may want to do a bone marrow biopsy. He’ll insert a needle into a bone, usually in your hip, to get a sample of bone marrow to check the number of plasma cells in it.

He may also want you to get X-rays. They can show spots of bone weakened by multiple myeloma. Sometimes you may also need a CT scan, MRI, or PET scan.


Several drugs and types of drugs are used to treat multiple myeloma.

Chemotherapy: You might get it alone or paired with another drug. The types of chemo most often used to treat multiple myeloma are:

  • Cyclophosphamide (Cytoxan)
  • Doxorubicin (Adriamycin)
  • Melphalan (Alkeran)
  • Liposomal doxorubicin (Doxil)
  • Panobinostat (Farydak)

Corticosteroids like dexamethasone or prednisone are often given with chemotherapy to reduce side effects.

Stem cell transplant: It won’t work for everyone, but if your doctor thinks you’re a good fit for it, they may start with a stem cell transplant. They will use a machine to remove some of your stem cells, then freeze and store them. Or they may use stem cells taken from a donor.

Next, you get high-dose chemotherapy. This will destroy almost all the cells in your bone marrow — both healthy cells and the plasma cells that cause the disease. Then the doctor will injects the stem cells into your veins. They travel to the bone marrow, where they multiply and make new, healthy blood cells.

Stem cell transplantation doesn’t cure multiple myeloma, but it often helps you live longer. It can also cause serious complications. For example, it can make you more likely to get infections.


Targeted Therapies

These medications target proteins, genes, or tissues and prevent cancer from growing.

Immunomodulatory drugs strengthen your immune cells to help them attack cancer cells. They also help starve the myeloma cells in your bone marrow by preventing new blood vessels from forming:

  • Lenalidomide (Revlimid)
  • Pomalidomide (Pomalyst)
  • Thalidomide (Thalomid)

Monoclonal antibodies help your immune system spot and destroy myeloma cells. You might hear your doctor call this immunotherapy:

  • Daratumumab (Darzalex)
  • Elotuzumab (Empliciti)

If you don’t have symptoms, your doctor might start you on one of these drugs to prevent myeloma from getting to a point where you need treatment.

Proteasome inhibitors stop the process that eats up extra proteins in cells. Myeloma cells make lots of proteins. When they build up, the cells die:

  • Bortezomib (Velcade)
  • Carfilzomib (Kyprolis)
  • Ixazomib (Ninlaro)

Your Treatment Plan

If you don’t have symptoms, your doctor may choose to watch you closely rather than start treatment right away.

If you do have symptoms, your doctor will work with you to come up with a treatment plan. It will aim to improve your quality of life by easing your symptoms and helping you get good nutrition. Your plan will have three main phases:

  • Induction therapy: Use medications to get quick control of the disease and its symptoms
  • Post-induction therapy: Add treatments like chemotherapy or a stem cell transplant (your doctor might also call it consolidation therapy)
  • Maintenance therapy: Keep your cancer at bay as long as possible

Which drugs your doctor chooses depends on your age and how aggressive your cancer is. Multiple myeloma cases are usually graded as high, intermediate, or standard risk. Most people start with a three-drug mix that combines a proteasome inhibitor, an immunomodulatory drug, and a corticosteroid. If you’re considered high risk, you might want to look into a clinical trial for an existing or new treatment. Research is ongoing, including clinical trials to identify more effective drugs and combinations.


Treating Symptoms

Often multiple myeloma has no symptoms. But if yours causes painful bone damage, your doctor might suggest:

Bisphosphonates: These drugs treat bone damage. Your doctor may have you try:

  • Pamidronate (Aredia)
  • Zoledronic acid (Zometa)

Be especially thorough with your brushing and flossing while you take these medications. It’s rare, but these medicines can damage your jaw. Dental work makes this more likely.

Radiation therapy. The doctor will direct a beam from a machine to a bone or other affected body part. The beam kills plasma cells, which can ease your pain and strengthen weakened bones.

What to Expect

Multiple myeloma varies widely among people. Some will live for years with few symptoms. With others, the condition gets worse quickly. Identifying the forms of multiple myeloma is often challenging for doctors.

Doctors have systems that predict survival rates. The simplest and most common uses the blood levels of two substances: albumin and beta-2-microglobulin. A higher albumin level and a lower beta-2-microglobulin level suggest a better chance for longer survival.

Other systems use multiple lab or DNA tests in plasma cells.

Knowing how aggressive your multiple myeloma is can help you and your doctor find the best plan for you.

What Your Doctor Is Reading

If you are interested in more advanced reading on this topic, we’ve made content from our health professional site, Medscape, available to you on WebMD.

WebMD Medical Reference Reviewed by Neha Pathak, MD on July 20, 2017


Abeloff, M. Abeloff’s Clinical Oncology, 4th edition, Churchill Livingstone, 2008.

American Cancer Society: “Multiple Myeloma: Detailed Guide.”

UpToDate: “Overview of the management of multiple myeloma,” “Patient Education: Multiple Myeloma treatment (Beyond the Basics).”

American Society of Clinical Oncology: “Multiple Myeloma: Treatment Options.”

© 2017 WebMD, LLC. All rights reserved.